Ananda Pharma Plc
Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.
ANAN | Aquis Stock Exchange
Overview
Corporate Details
- ISIN(s):
- GB00BDQPXQ60
- LEI:
- 894500DFM8VOC5FW4X47
- Country:
- United Kingdom
- Address:
- 6th Floor, 60 Gracechurch Street, EC3V 0HR London
- Website:
- https://www.anandapharma.co.uk/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Ananda Pharma Plc is a biopharmaceutical company focused on developing and commercializing regulatory-approved medicines derived from cannabinoids. The company targets complex conditions with significant unmet medical needs, primarily focusing on chronic inflammatory pain (including chemotherapy-induced peripheral neuropathy and endometriosis), drug-resistant epilepsies, and heart failure with preserved ejection fraction (HFpEF). Its integrated approach spans research, drug candidate development, clinical trials conducted with research partners, and navigating regulatory pathways for marketing authorization. Ananda Pharma leverages the well-understood safety profile of cannabinoids to potentially accelerate its clinical development programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-27 08:25 |
Legal Proceedings Report
Initial Data from Phase 1 Study
|
English | 22.7 KB | ||
| 2025-11-26 08:25 |
Delisting Announcement
Posting of Q&A
|
English | 15.3 KB | ||
| 2025-11-24 08:20 |
Delisting Announcement
Notice of General Meeting and Proposed Delisting
|
English | 29.2 KB | ||
| 2025-11-10 08:20 |
Regulatory Filings
Confirmation of receipt of £168k R&D tax refund
|
English | 23.0 KB | ||
| 2025-10-13 15:45 |
Interim / Quarterly Report
Interims for the six months ended 31 July 2025
|
English | 129.3 KB | ||
| 2025-09-26 12:10 |
Legal Proceedings Report
Ananda ends UCL/GOSH trials, prioritises MRX1
|
English | 22.6 KB | ||
| 2025-09-16 08:00 |
Regulatory Filings
Ananda attending Cannabinoid Summit
|
English | 22.1 KB | ||
| 2025-08-26 15:43 |
AGM Information
Result of Annual General Meeting
|
English | 29.6 KB | ||
| 2025-08-19 08:00 |
Report Publication Announcement
Webinar Presentation Release
|
English | 21.3 KB | ||
| 2025-07-30 14:49 |
Pre-Annual General Meeting Information
Notice of Annual General Meeting
|
English | 21.8 KB | ||
| 2025-07-30 13:44 |
Report Publication Announcement
Publication of Annual Report
|
English | 44.2 KB | ||
| 2025-06-23 08:00 |
Regulatory Filings
Key Milestone in MRX1 Path to Clinical Trials
|
English | 23.3 KB |
Automate Your Workflow. Get a real-time feed of all Ananda Pharma Plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ananda Pharma Plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ananda Pharma Plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
